No connection

Search Results

APLS vs LFST

APLS
Apellis Pharmaceuticals, Inc.
BEARISH
Price
$18.94
Market Cap
$2.42B
Sector
Healthcare
AI Confidence
85%
LFST
LifeStance Health Group, Inc.
NEUTRAL
Price
$6.40
Market Cap
$2.45B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
APLS
105.22
LFST
320.0
Forward P/E
APLS
-77.94
LFST
16.74
P/B Ratio
APLS
6.48
LFST
1.63
P/S Ratio
APLS
2.41
LFST
1.72
EV/EBITDA
APLS
42.6
LFST
34.04

Profitability

Gross Margin
APLS
60.34%
LFST
32.37%
Operating Margin
APLS
-25.58%
LFST
4.74%
Profit Margin
APLS
2.23%
LFST
0.68%
ROE
APLS
7.48%
LFST
0.65%
ROA
APLS
3.53%
LFST
0.73%

Growth

Revenue Growth
APLS
-5.9%
LFST
17.4%
Earnings Growth
APLS
--
LFST
--

Financial Health

Debt/Equity
APLS
1.28
LFST
0.31
Current Ratio
APLS
3.14
LFST
1.65
Quick Ratio
APLS
2.59
LFST
1.38

Dividends

Dividend Yield
APLS
--
LFST
--
Payout Ratio
APLS
0.0%
LFST
0.0%

AI Verdict

APLS BEARISH

APLS exhibits weak financial health per the Piotroski F-Score of 4/9, indicating a fragile foundation despite some positive gross margins and cash reserves. The company is unprofitable with negative operating margins and declining revenue, while insider selling activity and a bearish technical trend signal pessimism. Although the Graham Number ($3.44) and intrinsic value ($1.26) suggest deep undervaluation, the current price of $18.94 reflects high growth expectations that are not supported by fundamentals. The absence of an Altman Z-Score raises concern about default risk, especially given a debt/equity ratio of 1.28 and negative earnings. Analysts recommend 'buy' with a target of $33.60, but this optimism appears disconnected from deteriorating operational and financial trends.

Strengths
High gross margin of 60.34% indicates strong pricing power or low production costs
Current ratio of 3.14 and quick ratio of 2.59 suggest strong short-term liquidity
Positive earnings surprises in 2 out of the last 4 quarters (average +29.25%) show potential for upside in earnings execution
Risks
Piotroski F-Score of 4/9 indicates weak financial health and deteriorating fundamentals
Negative operating margin (-25.58%) and declining revenue (YoY -5.90%) signal ongoing operational inefficiencies
Insiders sold $1.47M worth of shares in the last 6 months with no buys, signaling lack of confidence
LFST NEUTRAL

LFST presents a stable but precarious financial profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided for bankruptcy risk assessment. While the company has successfully transitioned toward profitability with a promising forward P/E of 16.74, it trades at a massive premium compared to its Graham Number ($1.33) and Intrinsic Value ($0.14). Strong revenue growth of 17.4% is offset by razor-thin profit margins (0.68%) and aggressive insider selling totaling $32.51M. The stock is currently a speculative play on earnings expansion rather than a value-driven investment.

Strengths
Low Debt/Equity ratio of 0.31 indicating manageable leverage
Consistent revenue growth of 17.4% YoY and Q/Q
Successful transition from historical losses to positive EPS
Risks
Extreme trailing P/E ratio of 320.00
Heavy insider selling totaling $32.51M in the last 6 months
Razor-thin net profit margins of 0.68%

Compare Another Pair

APLS vs LFST: Head-to-Head Comparison

This page compares Apellis Pharmaceuticals, Inc. (APLS) and LifeStance Health Group, Inc. (LFST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile